SKLB1002

Research use only, not for human use.

SKLB1002 is a potent and ATP-competitive VEGFR2 inhibitor with IC50 of 32 nM.

SKLB1002 is a new potent VEGFR2 inhibitor, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation. Western blot analysis was conducted, which indicated that SKLB1002 inhibited VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal-regulated kinase, focal adhesion kinase, and Src. In vivo zebrafish model experiments showed that SKLB1002 remarkably blocked the formation of intersegmental vessels in zebrafish embryos. SKLB1002 inhibits angiogenesis and may be a potential drug candidate in anticancer therapy.

——

——

SKLB1002 | SKLB 1002 | SKLB1002

Others

Other Targets

VEGFR2

Cancer

——

1225451-84-2

320.39

C13H12N4O2S2

>98% (HPLC)

DMSO : 5.625 mg/mL 17.56 mM;

COc1c(OC)cc2c(Sc3nnc(C)s3)ncnc2c1

2-((6,7-dimethoxyquinazolin-4-yl)thio)-5-methyl-1,3,4-thiadiazole

(-20℃)

With Ice Pack

≥ 2 years